Materialise N.V. (NASDAQ: MTLS) is a Technology company in the Software - Application industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 33.82 | EPS (ttm) | 0.20 | Insider Own | - | Shs Outstand | 58.56M | Perf Week | 7.87% |
| Market Cap | 401.16M | Forward P/E | 23.51 | EPS next Y | 0.29 | Insider Trans | - | Shs Float | 23.50M | Perf Month | -1.15% |
| Enterprise Value | 316.97M | PEG | 2.71 | EPS next Q | 0.05 | Inst Own | - | Short Float | 0.68% | Perf Quarter | 25.92% |
| Income | 11.63M | P/S | 1.29 | EPS this Y | 23.39% | Inst Trans | - | Short Ratio | 3.06 | Perf Half Y | 32.75% |
| Sales | 310.69M | P/B | 1.36 | EPS next Y | 38.89% | ROA | 2.41% | Short Interest | 399.17K | Perf YTD | 23.42% |
| Book/sh | - | P/C | 16.96 | EPS next 5Y | 47.20% | ROE | 4.13% | 52W High | 7.47 -8.67% | Perf Year | 35.38% |
| Cash/sh | - | P/FCF | 56.48 | EPS past 3/5Y | - | ROIC | 3.13% | 52W Low | 4.76 43.31% | Perf 3Y | -10.81% |
| Dividend Est. | - | EV/EBITDA | 8.87 | Sales past 3/5Y | 5.93% 8.37% | Gross Margin | 57.60% | Volatility | 2.86% 3.24% | Perf 5Y | -68.53% |
| Dividend TTM | - | EV/Sales | 1.02 | EPS Y/Y TTM | -31.68% | Oper. Margin | 3.91% | ATR (14) | 0.22 | Perf 10Y | -1.15% |
| Dividend Ex-Date | - | Quick Ratio | 2.24 | Sales Y/Y TTM | 0.00% | Profit Margin | 3.76% | RSI (14) | 58.38 | Recom | 2.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.42 | EPS Q/Q | - | SMA20 | 4.03% | Beta | 1.34 | Target Price | 10.00 |
| Payout | 0.00% | Debt/Eq | 0.24 | Sales Q/Q | 11.43% | SMA50 | 2.04% | Rel Volume | 0.47 | Prev Close | 6.85 |
| Employees | 2,556 | LT Debt/Eq | 0.22 | Earnings | Aug 27 | SMA200 | 16.96% | Avg Volume | 123.86K | Price | 6.82 |
| IPO Date | Jun 25, 2014 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 194.96% -2.30% | Net Debt/EBITDA | -2.36 | Volume | 58,656 | Change | -0.40% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Feb-20-26 | Reiterated | Cantor Fitzgerald | $10 | |
| Mar-10-21 | Upgrade | Bryan Garnier | Neutral → Buy | |
| Apr-07-20 | Downgrade | Piper Sandler | Overweight → Neutral | |
| Jan-10-20 | Downgrade | KeyBanc | Overweight → Sector Weight | |
| Jul-06-15 | Downgrade | KBC Partners | Accumulate → Hold |
Materialise N.V. (MTLS), founded in 1990 and headquartered in Leuven, Belgium, is a global leader in additive manufacturing and medical technology. The company offers specialized software and comprehensive 3D printing services across the Americas, Europe, Africa, and Asia-Pacific regions. Its operations are divided into three core segments: 1. Materialise Software: This division develops sophisticated software solutions designed to empower and optimize the functionality of 3D printers and overall 3D printing workflows. Their software acts as a vital bridge, connecting various types of 3D printers with different software applications and data capture technologies, such as computer-aided design/manufacturing suites and 3D scanners. This segment serves a diverse clientele, including manufacturers of 3D printing equipment, production companies, and contract manufacturers in industries like automotive, aerospace, consumer goods, and hearing aids, as well as 3D printing service bureaus. Sales are conducted through their dedicated sales force, online platform, and a network of third-party distributors. 2. Materialise Medical: Focused on healthcare, this segment provides medical software that facilitates advanced medical-image-based analysis and engineering. This capability supports the personalized design of surgical devices and implants tailored to individual patients. Its customer base includes medical device companies, hospitals, universities, research institutions, and industrial firms, with sales handled by a direct sales team, their website, and through partnerships with picture archiving and communication system (PACS) providers. 3. Materialise Manufacturing: This segment delivers end-to-end 3D printing services. It encompasses design and engineering support, rapid prototyping, and the additive manufacturing of final production parts for a broad spectrum of industrial and commercial clients. Materialise N.V. also maintains significant collaboration agreements with several prominent companies in the medical field, including Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 289 | 290 | 289 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 126 | 124 | 125 | — | — | — | — | — | — | |
| Gross Profit | 163 | 166 | 163 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 109 | 109 | 110 | — | — | — | — | — | — | |
| Research and Development | 49 | 50 | 48 | — | — | — | — | — | — | |
| Other Operating Expense | -4 | 1 | -5 | — | — | — | — | — | — | |
| Operating Income | 9 | 6 | 10 | — | — | — | — | — | — | |
| Interest Expense | 4 | 6 | 2 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 7 | 8 | 7 | — | — | — | — | — | — | |
| Net Income Before Taxes | 10 | 8 | 15 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 1 | — | — | — | — | — | — | |
| Consolidated Net Income | 9 | 8 | 15 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 9 | 8 | 15 | — | — | — | — | — | — | |
| Net Income | 9 | 8 | 15 | — | — | — | — | — | — | |
| EPS (Recurring) | 0.17 | 0.15 | 0.25 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.17 | 0.15 | 0.25 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.17 | 0.15 | 0.25 | — | — | — | — | — | — | |
| EBITDA | 37 | 29 | 34 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 40.13 | 37.84 | 28.29 | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.39 | 1.13 | 1.44 | — | — | — | — | — | — | |
| Gross Margin | 56.40 | 57.24 | 56.40 | — | — | — | — | — | — | |
| Operating Margin | 3.11 | 2.07 | 3.46 | — | — | — | — | — | — | |
| Net Margin | 3.11 | 2.76 | 5.19 | — | — | — | — | — | — | |
| Shares Outstanding | 59 | 59 | 59 | — | — | — | — | — | — | |
| Market Capitalization | 403 | 327 | 415 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |